KENYA KIDD: Open Payments
NPI 1881601045 · SEATTLE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,042 in 93 payments from 27 companies in 2025. Trend: 2023 $1,237 · 2024 $2,026 · 2025 $2,042
Food & beverage: $1,949Education: $93
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 14 | $382 |
| Merck Sharp & Dohme LLC | 13 | $247 |
| Daiichi Sankyo Inc. | 9 | $213 |
| Novartis Pharmaceuticals Corporation | 9 | $177 |
| Incyte Corporation | 8 | $169 |
| Pharmacosmos Therapeutics Inc. | 4 | $97 |
| Regeneron Healthcare Solutions, Inc. | 4 | $91 |
| AstraZeneca Pharmaceuticals LP | 4 | $70 |
| GlaxoSmithKline, LLC. | 4 | $69 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $66 |
Products named: KEYTRUDA, DARZALEX, RYBREVANT, Enhertu, MONOFERRIC, JAKAFI, ERLEADA, LIBTAYO.
Industry payments across WA — which companies pay providers there.
